Skip to content

Released Aug 12, 2025, before the open

10-Q filed Aug 12, 2025, 43 days after period end · 0002023658-25-000098

Q2 2025 · 10-Q
Revenue—
Net Income-$27.39MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.50N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$32,018,000N/M
Operating Cash Flowderived-$25,594,000N/M
Free Cash Flowderived-$25,594,000N/M

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023
Net Income-$27.39M-$17.05M-$9.29M
EPS Diluted-$0.50-$19.01—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR